Reuters logo
BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution
December 1, 2017 / 12:10 PM / 16 days ago

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

Dec 1 (Reuters) - Lannett Company Inc:

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

* LANNETT COMPANY - ‍FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF JULY 21, 2018, TEN MONTHS FROM OFFICIAL NDA SUBMISSION DATE​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below